Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL) - Egyptian Knowledge Bank - troweb

238694

Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL)

Article

Last updated: 22 Jan 2023

Overview Similar Items

Article

Outcome of Second Line Chemotherapy (Gemcitabine, Dexamethasone, and Cisplatin) in Relapsed and Refractory Non Hodgkin Lymphoma

Article

ESHAP versus GEMOX in Management of Relapsed or Refractory Lymphoma: A Prospective Randomized Study

Article

Third line Treatment in Relapsed/Refractory Hodgkin's Lymphoma and Aggressive non-Hodgkin Lymphoma after 2nd line ESHAP or GEMOX

Article

Liposomal Doxorubicin based Chemotherapy in the treatment of Relapsed Diffuse Large B-cell Lymphoma

Article

Bendamustine in Refractory / Relapsed Non Hodgkin Lymphoma

Article

Treatment of relapsed classical Hodgkin lymphoma in the Brentuximab vedoitn era.

Article

Gemcitabine and Carboplatin in Patients with Refractory or Progressive Metastatic Breast Cancer after Treatment

Article

Efficacy of Ribavirin to Prevent Hepatitis Reactivation in Hepatitis C Virus-infected Patients Treated for Non-Hodgkin Lymphoma

Article

Combination of Cisplatin and Temozolomide Versus Carboplatin and Etoposide in the Treatment of Recurrent High Grade Glioma Patients

Article

Long Term Outcomes of Relapsed/Refractory Non-Hodgkin Lymphoma: A Single Center Experience